NZ703148A - Modified factor x polypeptides and uses thereof - Google Patents
Modified factor x polypeptides and uses thereofInfo
- Publication number
- NZ703148A NZ703148A NZ703148A NZ70314813A NZ703148A NZ 703148 A NZ703148 A NZ 703148A NZ 703148 A NZ703148 A NZ 703148A NZ 70314813 A NZ70314813 A NZ 70314813A NZ 703148 A NZ703148 A NZ 703148A
- Authority
- NZ
- New Zealand
- Prior art keywords
- factor
- polypeptides
- modified
- amino acid
- modified factor
- Prior art date
Links
- 101710136524 X polypeptide Proteins 0.000 title 1
- 108010014173 Factor X Proteins 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 108090000317 Chymotrypsin Proteins 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 229960002376 chymotrypsin Drugs 0.000 abstract 1
- 230000009852 coagulant defect Effects 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261741806P | 2012-07-25 | 2012-07-25 | |
| PCT/US2013/032616 WO2014018120A1 (en) | 2012-07-25 | 2013-03-15 | Modified factor x polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ703148A true NZ703148A (en) | 2016-08-26 |
Family
ID=48040462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ703148A NZ703148A (en) | 2012-07-25 | 2013-03-15 | Modified factor x polypeptides and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9145552B2 (OSRAM) |
| EP (1) | EP2877487B1 (OSRAM) |
| JP (2) | JP6363600B2 (OSRAM) |
| KR (1) | KR102049900B1 (OSRAM) |
| CN (1) | CN104755492A (OSRAM) |
| AU (1) | AU2013293573B2 (OSRAM) |
| BR (1) | BR112015001628A2 (OSRAM) |
| CA (1) | CA2879785C (OSRAM) |
| EA (1) | EA028865B1 (OSRAM) |
| ES (1) | ES2704083T3 (OSRAM) |
| IL (1) | IL236449B (OSRAM) |
| IN (1) | IN2015DN01404A (OSRAM) |
| MX (1) | MX365612B (OSRAM) |
| NZ (1) | NZ703148A (OSRAM) |
| SG (1) | SG11201500579SA (OSRAM) |
| WO (1) | WO2014018120A1 (OSRAM) |
| ZA (1) | ZA201500097B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1735439T3 (da) | 2004-04-12 | 2012-02-06 | Catalyst Biosciences Inc | Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1 |
| CA2626356C (en) | 2005-10-21 | 2017-08-22 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| ES2721266T3 (es) | 2006-07-05 | 2019-07-30 | Catalyst Biosciences Inc | Procedimientos de cribado de proteasas y proteasas identificadas por los mismos |
| KR20150067772A (ko) * | 2007-04-13 | 2015-06-18 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도 |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| AU2013293573B2 (en) | 2012-07-25 | 2016-10-27 | Catalyst Biosciences, Inc. | Modified Factor X polypeptides and uses thereof |
| AU2014326257B2 (en) | 2013-09-24 | 2017-08-10 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins |
| WO2015110939A1 (en) * | 2014-01-24 | 2015-07-30 | Pfizer Inc. | Compositions and methods for treating intracerebral hemorrhage |
| US10444715B2 (en) * | 2014-05-01 | 2019-10-15 | Belkin International, Inc. | Controlling settings and attributes related to operation of devices in a network |
| CN106536566A (zh) * | 2014-05-26 | 2017-03-22 | 莱顿教学医院 | 用于出血治疗的促止血蛋白 |
| EP3242936A1 (en) * | 2015-01-07 | 2017-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated factor x polypeptides and uses thereof for the treatment of haemophilia |
| WO2017017109A1 (en) * | 2015-07-27 | 2017-02-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated factor x polypeptides and uses thereof for the treatment of haemophilia |
| CN108472406A (zh) * | 2016-01-07 | 2018-08-31 | 艾欧生物医学有限责任公司 | 减少组织粘连的方法、组合物和试剂盒 |
| FR3050992A1 (fr) * | 2016-05-06 | 2017-11-10 | Lab Francais Du Fractionnement | Mutants du facteur x |
| FR3077296A1 (fr) * | 2018-02-01 | 2019-08-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Dimeres de variants du facteur x |
| WO2019201868A1 (en) * | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Coagulation factor based fusion protein with half-life extending polypeptide |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| EP3831843A1 (en) * | 2019-12-08 | 2021-06-09 | Royal College Of Surgeons In Ireland | A hemostatic agent and uses thereof |
| WO2023086388A1 (en) * | 2021-11-09 | 2023-05-19 | YewSavin, Inc. | Compositions and methods for treating bleeding and bleeding disorders |
| CN115725594B (zh) * | 2022-03-03 | 2024-11-08 | 南京医科大学 | Pipiserpin蛋白在蚊媒种群控制中的应用 |
| CN114681597A (zh) * | 2022-03-11 | 2022-07-01 | 兆科药业（合肥）有限公司 | 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用 |
| CN116426510B (zh) * | 2023-06-13 | 2023-09-22 | 北京沃森赛瑟生物技术有限公司 | 含修饰Xa因子的利伐沙班检测试剂盒及检测方法与应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AU6673898A (en) | 1997-03-07 | 1998-09-22 | Washington University | Factor x variant |
| US20030207402A1 (en) | 1997-08-22 | 2003-11-06 | Erhard Kopetzki | Autocatalytically activatable zymogenic precursors of proteases and their use |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6159722A (en) | 1997-12-03 | 2000-12-12 | Boehringer Mannheim Gmbh | Chimeric serine proteases |
| US20030186329A1 (en) | 1999-03-22 | 2003-10-02 | The Scripps Research Institute | Use of substrate subtraction libraries to distinguish enzyme specificities |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| AU1436401A (en) | 1999-10-21 | 2001-05-14 | Board Of Trustees Of The University Of Arkansas, The | RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof |
| US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| WO2002033089A2 (en) | 2000-10-05 | 2002-04-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ixodes scapularis tissue factor pathway inhibitor |
| CA2447023A1 (en) | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| US20030134298A1 (en) | 2001-07-03 | 2003-07-17 | Madison Edwin L. | Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon |
| AU2002347858A1 (en) | 2001-10-09 | 2003-04-22 | Dendreon Corporation | Transmembrane serine protease 25 |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| AU2002357004A1 (en) | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
| US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| AU2003247776A1 (en) | 2002-07-02 | 2004-01-23 | Dendreon Corporation | Serine protease 16 |
| FR2841904B1 (fr) * | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| CN101124484A (zh) | 2002-10-02 | 2008-02-13 | 催化剂生物科学有限公司 | 制备与筛选改变特异性蛋白酶的方法 |
| US20050048961A1 (en) | 2003-08-27 | 2005-03-03 | Jambo Networks, Inc. | System and method for providing communication services to mobile device users |
| WO2005023308A1 (en) | 2003-09-05 | 2005-03-17 | Maxygen Holdings Ltd. | Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins |
| WO2006101474A1 (en) | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| DE10350880A1 (de) | 2003-10-31 | 2005-06-02 | Roche Diagnostics Gmbh | Verfahren zur Bestimmung eines Analyten mittels einer Extraktionsschicht |
| DK1735439T3 (da) | 2004-04-12 | 2012-02-06 | Catalyst Biosciences Inc | Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1 |
| WO2005123119A2 (en) | 2004-06-10 | 2005-12-29 | Catalyst Biosciences, Inc. | Administration of neutral endopeptidase to treat inflammatory bowel disease |
| EP1726643A1 (en) | 2005-05-27 | 2006-11-29 | Direvo Biotech AG | Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| CA2626356C (en) | 2005-10-21 | 2017-08-22 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| EP2423306A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| ES2721266T3 (es) | 2006-07-05 | 2019-07-30 | Catalyst Biosciences Inc | Procedimientos de cribado de proteasas y proteasas identificadas por los mismos |
| KR20150067772A (ko) | 2007-04-13 | 2015-06-18 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도 |
| PL2193196T3 (pl) | 2007-09-28 | 2017-07-31 | Portola Pharmaceuticals, Inc. | Antidotum na czynnik inhibitora XA oraz sposoby jego stosowania |
| DK2202306T3 (da) | 2007-10-09 | 2013-01-21 | Chemo Sero Therapeut Res Inst | Rekombinant faktor x uden glycosylering og fremgangsmåde til fremstilling deraf |
| EP2252316A2 (en) | 2008-02-07 | 2010-11-24 | Andrew Baker | Modulation of adenoviral tropism |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| CN102105582A (zh) * | 2008-04-21 | 2011-06-22 | 诺沃-诺迪斯克有限公司 | 高糖基化人凝血因子ix |
| SMT202300084T1 (it) | 2008-09-15 | 2023-05-12 | Uniqure Biopharma B V | Mutante del polipeptide del fattore ix, suoi usi ed un metodo per la sua produzione |
| JP5709316B2 (ja) | 2008-11-14 | 2015-04-30 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法 |
| US8436144B2 (en) | 2008-12-19 | 2013-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| PL3604510T3 (pl) | 2009-03-30 | 2025-07-28 | Alexion Pharmaceuticals, Inc. | Antidota na inhibitory czynnika xa i sposoby ich stosowania |
| JP6163304B2 (ja) | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法 |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| AU2012315516B2 (en) | 2011-09-30 | 2017-05-04 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
| AU2013293573B2 (en) | 2012-07-25 | 2016-10-27 | Catalyst Biosciences, Inc. | Modified Factor X polypeptides and uses thereof |
-
2013
- 2013-03-15 AU AU2013293573A patent/AU2013293573B2/en not_active Ceased
- 2013-03-15 EA EA201500172A patent/EA028865B1/ru not_active IP Right Cessation
- 2013-03-15 EP EP13713325.2A patent/EP2877487B1/en active Active
- 2013-03-15 US US13/815,768 patent/US9145552B2/en not_active Expired - Fee Related
- 2013-03-15 MX MX2015001083A patent/MX365612B/es active IP Right Grant
- 2013-03-15 SG SG11201500579SA patent/SG11201500579SA/en unknown
- 2013-03-15 BR BR112015001628A patent/BR112015001628A2/pt not_active IP Right Cessation
- 2013-03-15 CN CN201380049692.2A patent/CN104755492A/zh active Pending
- 2013-03-15 IN IN1404DEN2015 patent/IN2015DN01404A/en unknown
- 2013-03-15 WO PCT/US2013/032616 patent/WO2014018120A1/en not_active Ceased
- 2013-03-15 NZ NZ703148A patent/NZ703148A/en not_active IP Right Cessation
- 2013-03-15 ES ES13713325T patent/ES2704083T3/es active Active
- 2013-03-15 CA CA2879785A patent/CA2879785C/en not_active Expired - Fee Related
- 2013-03-15 JP JP2015524250A patent/JP6363600B2/ja not_active Expired - Fee Related
- 2013-03-15 KR KR1020157004694A patent/KR102049900B1/ko not_active Expired - Fee Related
-
2014
- 2014-04-03 US US14/244,840 patent/US9856467B2/en active Active
- 2014-12-25 IL IL236449A patent/IL236449B/en active IP Right Grant
-
2015
- 2015-01-07 ZA ZA2015/00097A patent/ZA201500097B/en unknown
-
2018
- 2018-06-28 JP JP2018123235A patent/JP2018183147A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014018120A1 (en) | 2014-01-30 |
| US20140234290A1 (en) | 2014-08-21 |
| JP2018183147A (ja) | 2018-11-22 |
| US9145552B2 (en) | 2015-09-29 |
| EP2877487A1 (en) | 2015-06-03 |
| ZA201500097B (en) | 2016-09-28 |
| ES2704083T3 (es) | 2019-03-14 |
| BR112015001628A2 (pt) | 2017-11-07 |
| MX365612B (es) | 2019-06-07 |
| HK1210790A1 (en) | 2016-05-06 |
| EA028865B1 (ru) | 2018-01-31 |
| CA2879785C (en) | 2019-06-18 |
| JP6363600B2 (ja) | 2018-07-25 |
| KR102049900B1 (ko) | 2019-11-28 |
| AU2013293573A1 (en) | 2015-02-05 |
| IL236449B (en) | 2019-02-28 |
| SG11201500579SA (en) | 2015-02-27 |
| EP2877487B1 (en) | 2018-10-17 |
| AU2013293573B2 (en) | 2016-10-27 |
| US20140030247A1 (en) | 2014-01-30 |
| IL236449A0 (en) | 2015-02-26 |
| US9856467B2 (en) | 2018-01-02 |
| EA201500172A1 (ru) | 2015-09-30 |
| IN2015DN01404A (OSRAM) | 2015-07-03 |
| MX2015001083A (es) | 2015-04-08 |
| KR20160073937A (ko) | 2016-06-27 |
| JP2015524801A (ja) | 2015-08-27 |
| CN104755492A (zh) | 2015-07-01 |
| CA2879785A1 (en) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ703148A (en) | Modified factor x polypeptides and uses thereof | |
| EP4403631A3 (en) | Serine proteases | |
| EP3486319A3 (en) | Compositions and methods comprising serine protease variants | |
| MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
| EA201691558A1 (ru) | Удаление сериновых протеаз путем обработки тонкоизмельченным диоксидом кремния | |
| MX2012001346A (es) | Polipeptidos del factor ix modificados y usos de los mismos. | |
| CY1121519T1 (el) | Καθαρισμος της υδουρονικης-2-σουλφατασης | |
| MX336737B (es) | Composiciones y metodos que comprenden variantes de proteasa serina. | |
| PH12015501983A1 (en) | Peptides and compositions for treatment of joint damage | |
| MX2015017103A (es) | Celulas beta derivadas de células madre ( sc-beta ) y composiciones y métodos para generarlas. | |
| CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
| MX383346B (es) | Composiciones y metodos que comprenden variantes de serina proteasa. | |
| MX2016007711A (es) | Serpinas modificadas para el tratamiento de trastornos de la coagulacion. | |
| MX336731B (es) | Composiciones y metodos para potenciar la actividad de proteasoma. | |
| MY156851A (en) | Azeotropic and azeotrope-like compositions of methyl perfluoroheptene ethers and trans-1,2-dichloroethylene and uses thereof | |
| MX379863B (es) | Composiciones y metodos relacionados con una toxina mutante de clostridium difficile | |
| MX2019006425A (es) | Estabilizacion de enzimas en composiciones. | |
| PH12014502763A1 (en) | Method for the degradation of keratin and use of the keratin hydrolysate produced | |
| MX2025002623A (es) | Composiciones que comprenden arng y sus usos en el tratamiento de la deficiencia de alfa-1 antitripsina | |
| BR112012019042A2 (pt) | "inibidores de serina protease tipo tripsina, e sua preparação e uso". | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX2010002769A (es) | Preparacion recombinante de fracciones de bromelaina seleccionadas. | |
| MX2017007554A (es) | Detergentes y agentes de limpieza que comprende una combinacion de amilasa y proteasa. | |
| MX2015006986A (es) | Solucion de trombina y metodos de uso de esta. | |
| MX2016012428A (es) | Aumento de la expresion de proteina recombinante con cobre. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20170228 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2019 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20180305 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20190301 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2021 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20200303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2022 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20210224 |
|
| LAPS | Patent lapsed |